https://www.selleckchem.com/pr....oducts/tiragolumab-a
The follow up period was 54.7 months (range, 21 days to 40.5 months). Pooled technical success rate was 97% (95% CI-92-99%, I 83%). Clinical success rates at ≤3 months, 3-12 months, and 12 months were 82% (95% CI-70-90%, I 42%), 86% (95% CI-75-92%, I 44%), and 88% (95% CI-83-91%, I 0%), respectively. There was no significant difference in the technical or clinical success between acute and chronic pancreatitis on subgroup analysis. Mortality was lower in chronic pancreatitis (OR 4.27 (95% CI 1.35-13.53, I 0%)). Spleni
Like
Comment
Share
